NCT04543617 2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3 Active not recruiting
Clinical Trials
126 trialsNCT04661150 2026-04-16
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03175432 2026-04-15
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05470595 2026-04-15
LCNEC-ALPINE
Technische Universität Dresden
Phase 2 Active not recruiting
NCT06760481 2026-04-15
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02912559 2026-04-14
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06077500 2026-04-14
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT02839707 2026-04-13
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT02883062 2026-04-13
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02997228 2026-04-13
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03141684 2026-04-13
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03148418 2026-04-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03237780 2026-04-13
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03321643 2026-04-13
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03540420 2026-04-13
ACHILES
Norwegian University of Science and Technology
Phase 2 Active not recruiting
NCT03775265 2026-04-13
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03811002 2026-04-13
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04214262 2026-04-13
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04310020 2026-04-13
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04334941 2026-04-13
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04458922 2026-04-13
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05063552 2026-04-13
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT05211323 2026-04-13
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05286801 2026-04-13
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05411081 2026-04-13
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05595460 2026-04-13
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
RayzeBio, Inc.
Phase 1 Active not recruiting
NCT04180072 2026-04-09
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
National Health Research Institutes, Taiwan
Phase NA Active not recruiting
NCT03093922 2026-04-07
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04138628 2026-04-07
TOMBOLA
Aarhus University Hospital
Phase 2 Active not recruiting
NCT04560972 2026-04-07
LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03533283 2026-04-06
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05112965 2026-04-06
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05047250 2026-04-03
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04589845 2026-04-02
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04820179 2026-04-02
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
University of Arizona
Phase 2 Active not recruiting
NCT03614949 2026-04-01
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04729959 2026-04-01
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04660344 2026-03-27
IMvigor011
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04158258 2026-03-24
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT04637594 2026-03-20
IMAGINE
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT04102098 2026-03-19
IMbrave050
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05142696 2026-03-17
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
Phase 1/2 Active not recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05689671 2026-03-10
ANTELOPE
Charite University, Berlin, Germany
Phase 4 Active not recruiting
NCT03178552 2026-03-09
B-FAST
Hoffmann-La Roche
Phase 2/3 Active not recruiting
NCT04020809 2026-03-09
Neoadjuvant Atezolizumab in Cutaneous Melanoma
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT04563338 2026-03-05
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
University Health Network, Toronto
Phase 2 Active not recruiting